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Abstract We aimed to compare two different salvage
treatment strategies for relapsed high-grade glioma (HGG)
patients by means of a new prognostic model. A simplified
version of the so-called HGG-Immuno RPA model esti-
mates the prognosis of relapsed HGG patients and distin-
guishes three different prognostic classes (I = good,
II = intermediate, III = poor). The model has been con-
structed with a cohort of 117 patients whose salvage
treatment consisted of re-operation followed by dendritic
cell vaccination (ReOP ? DCV). However, using only the
predictors histology, age and performance status, the sim-
plified HGG-Immuno RPA model is basically independent
from treatment. In the present study we applied the sim-
plified model to the cohort used to construct the original
HGG-Immuno RPA model and another cohort of 165
patients who underwent re-irradiation (ReRT) at relapse.
Then, we compared the outcomes achieved by the two
different salvage treatments in each prognostic class. The
model predicted good, intermediate and poor prognosis for
11, 31 and 75 patients of the ReOP ? DCV cohort and for
20, 39 and 106 patients of the ReRT cohort, respectively.
Neither of the two strategies was superior to the other. In
the groups with good, intermediate and poor prognosis
12-months survival rates were 73, 59 and 25 % after
ReOP ? DCV and 72, 36 and 23 % after ReRT, respec-
tively. Being easy to handle and independent from treat-
ment, the aforementioned model is useful for therapeutic
decisions. ReRT and ReOP ? DVC seem to be equally
effective. The choice of salvage treatment should be based
on the expected side effects.
Thomas Hundsberger and Brigitta G. Baumert have contributed
equally to this article.
& Klaus Mu¨ller
klausmueller1978@googlemail.com
1 Department of Radiation Oncology, University of Leipzig
Medical Center, Leipzig, Germany
2 Department of Radiation Oncology, Hospital Chemnitz,
Bu¨rgerstraße 2, 09113 Chemnitz, Germany
3 Department of Radiation Oncology, Cantonal Hospital St.
Gallen, St. Gallen, Switzerland
4 Department of Radiation Oncology, University Hospital
Tu¨bingen, Tu¨bingen, Germany
5 Laboratory of Experimental Immunology, Catholic
University Leuven, Leuven, Belgium
6 Division of Pediatric Hematology and Oncology, Department
of Pediatrics and Adolescent Medicine, University Medical
Center Go¨ttingen, Go¨ttingen, Germany
7 Department of Radiation Oncology (MAASTRO), GROW
(School for Oncology & Developmental Biology), University
of Maastricht Medical Center, Maastricht, The Netherlands
8 Division of Pediatric Oncology, Hematology and
Hemostaseology, Department of Woman’s and Children’s
Health, University Hospital Leipzig, Leipzig, Germany
9 Department of Radiation Oncology, Medical Faculty,
Heinrich Heine University of Du¨sseldorf, Du¨sseldorf,
Germany
10 Departments of Neurology and Haematology/Oncology,
Cantonal Hospital St. Gallen, St. Gallen, Switzerland
11 Clinical Cooperation Unit Neurooncology, Department of
Radiation Oncology, MediClin Robert Janker Clinic &
University of Bonn Medical Center, Bonn, Germany
123
J Neurooncol
DOI 10.1007/s11060-015-1844-8
Keywords Relapsed high-grade gliomas  Prognostic
model  Re-irradiation  Dendritic cell vaccination 
Recurrent glioblastoma  Salvage treatment  Prognosis
Background
The best treatment approach for relapsed high-grade glio-
mas (HGG) is currently unknown. Randomized trials on
the topic are sparse. Thus, for clinical decision making
physicians mostly have to rely on experiences from small
retrospective series [1–6]. Prognostic models for post-re-
lapse survival may be beneficial for the rational choice of
salvage treatment since they may enhance the compara-
bility of heterogeneous patient cohorts by defining homo-
geneous subsets of patients with similar intrinsic prognosis.
Within these subsets more accurate comparisons of dif-
ferent salvage strategies may be drawn. Recently, a simple
recursive partitioning analysis (RPA) model for the sur-
vival of relapsed HGG patients undergoing re-operation
followed by dendritic cell vaccination (ReOP ? DCV) was
suggested. The so-called HGG-Immuno RPA model dis-
tinguished four prognostic classes (
I = excellent, II = good, III = intermediate, IV =
poor), which were characterized by different survival rates
[7].
The purpose of the present study was:
(1) To validate the reproducibility of a simplified
version of the HGG-Immuno RPA model in terms
of discrimination with an independent patient cohort.
(2) To compare two different salvage treatments: re-
irradiation (ReRT) versus re-operation followed by
dendritic cell vaccination (ReOP ? DCV) by means
of the model.
Patients and methods
The HGG-Immuno RPA model
Recursive partitioning analysis is a statistical technique
which is used to define prognostic classes based on treat-
ment and/or pre-treatment prognostic variables (predictors)
[8]. The HGG-Immuno RPA model was recently suggested
for the prognostic classification of relapsed HGG patients
undergoing re-operation followed by dendritic cell vacci-
nation [7]. The original model was constructed with a
cohort of 117 adult patients included in the early phase of
the HGG-Immuno-2003 trial (ReOP ? DCV cohort) [9]. It
distinguishes four prognostic classes (I = excellent,
II = good, III = intermediate, IV = poor) and is based on
four predictors (age, WHO grading, performance status and
mental status) [7].
For this study, however, we used a simplified version of
the model in which the predictor ‘‘mental status’’ was
omitted. As this parameter is only decisive in the prog-
nostic classes III and IV of the original model, these classes
were merged together forming a joint poor prognosis group
(‘‘class III’’) (Fig. 1).
Patient cohorts
We applied the simplified version with three different
prognostic classes (I = good, II = intermediate, III = -
poor) to
(a) the patient cohort used to construct the original
model (‘‘ReOP ? DCV cohort’’) and
(b) an independent, multicenter cohort of 165 relapsed
HGG patients who underwent a second course of
radiation therapy (ReRT) instead of ReOP ? DCV
(‘‘ReRT cohort’’).
Detailed information on patient characteristics, treat-
ment and outcome of the ReOP ? DCV cohort has already
been published [7]. Survival time was defined as the time
Fig. 1 2 HGG-IMMUNO recursive partitioning analysis (RPA)
models to predict the prognosis of relapsed HGG patients. a Original
HGG-IMMUNO RPA tree in relapsed high-grade glioma (HGG)
patients as suggested by Vleeschouwer et al. [7]. b Simplified version
of the aforementioned model which may be used whenever mini
mental state examination was not performed
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from pre-vaccine re-operation to death or to last follow-up.
In the ReRT cohort follow-up time of survivors (n = 32)
ranged from 0.6 to 69.1 months (median, 8.5 months). For
this cohort, survival time was defined as the time from the
start of re-irradiation to death or to last follow-up. The
dataset was collected from four different hospitals, namely
the University Hospital of Leipzig (Germany) (n = 64
patients), the University Hospital of Tu¨bingen (Germany)
(n = 31 patients), the Cantonal Hospital of St. Gallen
(Switzerland) (n = 13 patients) and the University Hospi-
tal of Maastricht (The Netherlands) (n = 57 patients).
Characteristics and outcome of the patients from Leipzig,
Tu¨bingen and St. Gallen have already been published [10–
12]. Of note, a significant proportion of the re-irradiated
patients also underwent ReOP.
Working assumption
As the predictors of the simplified model (age, histology and
performance status) are not related to therapy, we set up the
hypothesis that it would keep its ability to discriminate
patients with different prognoses in both cohorts or, in other
words, independently of the treatment strategy used. More-
over, we postulated that if one salvage treatment was more
efficient than the other in terms of post-treatment survival
calibration of the model would differ between both cohorts.
Methodological approach
The prognostic model was validated with a patient cohort
independent from the one used to construct it. We
addressed the two fundamental aspects of a prognostic
model’s performance: discrimination and calibration. Dis-
crimination reflects the ability of a model to characterize
subsets of patients with different prognoses. Calibration
usually reflects prediction accuracy [13, 14]. However, in
this study, calibration reflects the extent to which the anti-
tumoral potentials of the two different salvage treatments,
ReRT and ReOP ? DCV, match each other.
Our analysis included the following four steps:
(1) In both cohorts discrimination and calibration of the
RPA model were roughly checked by visual com-
parison of the survival curves corresponding to the
three RPA classes (Fig. 2).
(2) In both cohorts discrimination was assessed calcu-
lating hazard ratios for deaths (Cox regression
analysis) for the RPA classes I and II and plotting
them in the form of a tree . The worst prognostic
class III served as reference (Fig. 3).
(3) For each RPA class calibration was separately
checked by visual comparison of the Kaplan–Meier
survival curve in the re-irradiation cohort with its
counterpart in the vaccination cohort and the corre-
sponding 95 % confidence intervals (CIs) (Fig. 4).
(4) By means of calibration plots the 9-, 12- and
15-months survival probabilities of the vaccinated
patients (X-axis) were related to the Kaplan–Meier
estimates of the re-irradiated patients (Y-axis). In
such a calibration plot Kaplan–Meier estimates close
to the bisecting line indicate that the two compared
treatments are equally effective (Fig. 5).
Fig. 2 Kaplan–Meier survival plots according to the three different RPA classes in a the vaccination (ReOP ? DCV) cohort and b the re-
irradiation (ReRT) cohort
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The follow-up time of the patients was quantified
according to the method suggested by Schemper and Smith
[15].
The statistical computations of the follow-up time and
(1) were performed with SPSS, version 20.0. The statistical
computations of (2), (3) and (4) were performed with R,
version 3.0.3.
Results
Baseline patient characteristics and outcomes
The characteristics of both treatment cohorts
(ReOP ? DCV versus ReRT) are shown in Table 1.
In the ReOP ? DCV cohort 95 patients (81.2 %) died
during the period of observation. Median follow-up time
was 34.6 ± 3.5 months. Median survival times after
ReOP ? DCV were 48.4, 16.0 and 7.5 months in the
classes with good, intermediate and poor prognosis,
respectively.
In the ReRT cohort 133 patients (80.6 %) died during
the period of observation. Median follow-up time was
30.7 ± 10.9 months. Median survival times after ReRT
were 18.2, 10.3 and 7.8 months in the classes with good,
intermediate and poor prognosis, respectively.
The 6- and 12-month overall survival rates of the
different prognostic classes sorted by treatment
(ReOP ? DCV versus ReRT) are listed in Table 2.
Step 1: visual comparison
Figure 2a shows the Kaplan–Meier survival curves of the
117 patients who underwent ReOP ? DCV according to
the three prognostic classes of the simplified HGG-Immuno
RPA model. Figure 2b shows the corresponding curves of
the 165 re-irradiated patients. Both in Fig. 2a and b the
survival curves of the three different prognostic classes I, II
and III separate nicely from each other—a finding which
suggests the validity of the simplified RPA model.
Step 2: quantifying discrimination of the simplified HGG-
Immuno RPA model in both treatment cohorts
Using both the vaccination cohort and the re-irradiation
cohort, we calculated the hazard ratios for death (HR) of
the prognostic classes I and II. The worst prognostic class
(III) served as reference (Fig. 3). The HR can be inter-
preted as the chance of death occurring in the corre-
sponding prognostic class divided by the chance of death
occurring in the worst prognostic class. Ideally, the HR for
the corresponding risk classes should satisfy two criteria.
First, the HR should increase steadily and clearly as the
risk class increases, indicating a higher hazard of death in
the more unfavorable prognostic classes. Second, the HR
should remain clearly below a value of 1.0, as class III has
the worst prognosis by definition. Both criteria are fulfilled
in both treatment cohorts (Fig. 3).
Step 3: assessing treatment benefit by a comparison
of survival plots sorted by RPA class
For each RPA class the survival plot of re-irradiated
patients (colored) was compared with the survival plot of
vaccinated patients (black) and its corresponding 95 %
confidence intervals (black, dashed). Colored curves loca-
ted between the two black-dashed lines suggest that ReRT
and ReOP ? DCV are similar with regards to effectivity.
This criterion is best fulfilled in RPA class III i.e. in the
patients with the worst prognosis. For class I the 95 % CI is
extremely wide due to the small sample size, a fact, cer-
tainly reducing the meaningfulness of the analysis
(Figure 4).
Step 4: comparing treatment benefit by means
of ‘‘calibration curves’’ for the time points 9, 12
and 15 months after the start of salvage treatment
Figure 5 demonstrates the calibration curves sorted by
RPA class. The 9-, 12- and 15 months survival rates of the
different RPA classes in the ReRT cohort (Y-axis) are
compared with the corresponding survival rates in the
ReOP ? DCV cohort (X-axis). The colored vertical lines
Fig. 3 Tree plot of the hazard ratios for deaths according to RPA
classes. Hazard ratios for deaths of RPA classes I and II in the
vaccination (ReOP ? DCV) cohort (above) and in the re-irradiation
(ReRT) cohort (below). RPA class III served as reference
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represent the 95 % confidence intervals of the respective
survival rates in the ReRT cohort. Vertical lines crossing
the bisecting line indicate that ReRT and ReOP ? DCV
are equally effective. This criterion is best fulfilled in RPA
class III i.e. in the patients with the worst prognosis
(Fig. 5).
Discussion
The treatment of newly diagnosed Glioblastoma is highly
standardized and currently comprises surgery followed by
radiation therapy plus concomitant and adjuvant temo-
zolomide. In anaplastic gliomas molecular markers like 1p/
19q codeletion and IDH mutations will strongly guide
treatment [16]. In contrast, the optimal salvage treatment
approach after relapse has not been determined yet and
prospective, randomized trials are sparse. Although a ple-
thora of mono- and combination chemotherapy strategies
have been evaluated, an obvious survival benefit has not
been achieved with any particular regimen to date [17].
The role of re-operation is controversially discussed. Some
authors observed that second surgery was of limited value
for survival if complete resection could not be achieved.
Accordingly, they recommended cytoreductive therapy
only in symptomatic patients [4, 5]. Others argued that re-
operation might be associated with considerable morbidity
and mortality [18]. In contrast, there is also a study
claiming that repeated (incomplete) resections may result
in improved survival and that the risk of iatrogenic deficits
caused by repeated surgery is low [19]. Postoperative
dendritic cell (DC) vaccination is a relatively new and
potentially promising approach exploiting the stimulation
of the host immune system against tumor antigens [20].
Adjuvant DC based immunotherapy is safe and feasible for
a considerable number of patients. However, the extent of
resection at the start of vaccination is critical for success [7,
9, 21]. Re-irradiation has been widely accepted as a salvage
therapy in recurrent gliomas with stereotactic fractionated
radiotherapy being the most frequent technique. Toxicity
has been overestimated for a long time [6, 18]. The anti-
tumoral effect of re-irradiation may be enhanced by radio-
sensitizing agents. For instance, the results of the
prospective, randomized APG101 study indicate a benefit
of combining re-irradiation with CD95 pathway inhibition
[22]. The National Comprehensive Cancer Network and
Canadian (NCCN) guidelines for recurrent or progressive
bFig. 4 Comparison of survival plots sorted by RPA class. Survival
plot of the ReRT cohort (coloured) compared with the survival plot of
the ReOP ? DCV cohort (black) and its corresponding 95 %
confidence interval (back, dashed) for the RPA-classes I-III
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glioblastoma recommend a second course of radiotherapy
in local recurrence to be considered, especially if there has
been a long interval since prior irradiation and/or if there
has been a good response to first-line treatment [23].
Additionally, a recent European review concluded that
patients with a Karnofsky performance score (KPS) greater
than 60 %, progression more than 6 months from time of
surgery and a tumor size of up to 40 mm were the best
candidates [17]. The ongoing Radiation Therapy Oncology
Group (RTOG) 1205 trial is evaluating the benefit of re-
irradiation in a prospective and randomized setting (con-
current bevacizumab and re-irradiation versus beva-
cizumab alone as treatment for recurrent glioblastoma).
Due to the small number of prospective, randomized
trials on relapsed HGG retrospective comparisons of
competing salvage treatment strategies remain indispens-
able for clinical decision making to date. However, a
confusing variety of potential prognostic factors, con-
founders and heterogeneous patient cohorts make bench-
marking extremely difficult. In our opinion, simple, reliable
and reproducible models classifying patients into homo-
geneous subgroups with similar intrinsic prognosis would
be a way out of the dilemma. Of note, such models should
ideally be based on predictors which are not related to a
particular treatment (‘pre-treatment variables’). The pre-
dictor ‘‘extent of resection’’, for instance, would not be
appropriate as it implies repeated tumor resection. In 2012,
the so-called HGG-Immuno RPA model was suggested.
However, although being independent from treatment and
perfectly meeting the criterion of simplicity, the model
lacked successful validation with an independent patient
cohort [7]. The present analysis now bridges this gap and
certifies a simplified version of the model as fit for purpose.
Simplification of the original model was mandatory
because the predictor ‘‘mental status’’ had not been asses-
sed in the majority of patients used for validation. This
means that there are only three instead of four different
prognostic classes and that patients aged C50 years and
diagnosed with glioblastoma are always in the worst
prognostic group. KPS or mental status, do not have an
additional meaning for their prognosis. We furthermore
used the simplified model to compare two alternative sal-
vage treatments (ReRT and ReOP ? DCV) with each
other. Although completely different neither of the two
bFig. 5 Calibration plots. Referring to certain time points (9, 12 and
15 months after the start of salvage treatment), the calibration plots
compare the survival rates of the vaccinated patients sorted by the
different RPA classes (X-axis) with the respective survival rates and
their 95 % confidence intervals of the re-irradiated patients (Y-axis).
Kaplan–Meier estimates close to the bisecting line indicate that re-
irradiation and re-operation followed by adjuvant DC vaccination are
equally effective
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strategies was clearly superior to the other. Of note, in all
prognostic classes we observed a tendency to slightly
shorter survival times in the ReRT cohort, which was most
evident in class II. However, this may be due to the fact
that in the re-irradiated patients survival time was calcu-
lated from the start of re-irradiation, although a consider-
able number of these patients underwent prior
cytoreductive re-surgery. In contrast, in the ReOP ? DCV
cohort, survival was calculated from the time-point of re-
operation.
Naturally, it would be desirable to use the model for
further studies assessing alternative salvage treatment
approaches. Therefore, we are currently compiling a new
dataset of relapsed high-grade glioma patients who
received chemotherapy ± bevacizumab as salvage treat-
ment. We hope to be able to present first results soon.
Conclusions
In summary, the prognostic model’s ability to discriminate
patients with good, intermediate or bad prognosis was
demonstrated in the cohort of re-irradiated patients. Being
easy to handle and independent from the applied salvage
treatment strategy, the simplified HGG-Immuno RPA model
appears to be useful for therapeutic decision making. ReRT
andReOP ? DVCseem tobe similarwith regards to efficacy.
The choice between these two options for salvage treatment
should mainly be based on the expected side effects.
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